Q2 2026 Teleflex Incorporated Earnings Call Presentation

Teleflex Incorporated

Conference Call Logistics

The release, accompanying slides, and replay webcast are available online at https://www.teleflex.com (click on Investors)

An audio replay of the call will be available beginning at 11:00 am Eastern Time on August 6, 2026 either on the Teleflex website or by telephone.

The call can be accessed by dialing

(all other locations).

The confirmation code is 69028.

Today's Speakers

President and CEO

Executive VP and CFO

VP, Investor Relations and Strategy Development

TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Note on Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings per share and, in each case, our estimates with respect to the items expected to impact those forecasted results; statements regarding our planned uses of the net proceeds from the closing of the sale of our OEM business (the "OEM Strategic Divestiture"), including, without limitation, with respect to the paydown of debt and the repurchase of shares our outstanding common stock; our plans to commence an accelerated share repurchase; statements regarding our expectations with respect to the timing for closing of the sales of our Acute Care and Interventional Urology businesses (which, together with the OEM Strategic Divestiture, we refer to as the "Strategic Divestitures"); statements regarding projected costs, savings and timing with respect to restructuring activities related to the Strategic Divestitures; our expectation that the transition services and manufacturing services agreements to be entered into in connection with the Strategic Divestitures will offset stranded costs on an annualized basis; our expectation that our financial portfolio will be meaningfully stronger starting in 2027; statements regarding our BIOMAG-II and BIOMAG-III pivotal trials; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation. You should not place undue reliance on these statements or the scientific data presented.

Note on Non-GAAP Financial Measures

This presentation refers to certain non-GAAP financial measures, including, but not limited to, pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins, adjusted selling, general and administrative expenses, adjusted research and development expenses, adjusted income before taxes, adjusted income tax expense and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

Additional Notes

This document contains certain highlights with respect to our second quarter 2026 results and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended June 30, 2026 located in the investor section of our website at https://www.teleflex.com and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the Securities and Exchange Commission.

Unless otherwise noted, the following slides reflect continuing operations.

4 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Executive Overview

Q2'26 Highlights

Q2

Performance Summary

• Q2'26 pro forma adjusted constant currency revenue grew 4.7%

  year-over-year

• Q2'26 adjusted gross margin of 61.7% and adjusted operating margin of 19.6%

• Q2'26 adjusted EPS of $1.76, a 1.7% increase year-over-year

OEM Divestiture Update

• Closed the OEM Strategic Divestiture for approximately $1.5 billion in proceeds ($1.25 billion after-tax)

• OEM Strategic Divestitures generates the majority of our expected

d

proceeds from the Strategic Divestitures - funds debt paydown an

share repurchase

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Innovation Updates

EZPLAZTM Freeze Dried Plasma Receives FDA BLA Approval

• First freeze dried plasma licensed by the FDA; expands the emergency medicine portfolio within our Vascular and Emergency Medicine business

• Approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage), when plasma is required and other plasma products are not available

• Enables plasma transfusion in situations where it is critically needed - on the battlefield, in the hospital, and on air and road ambulances

• Patented flexible plastic bag technology enables quick and efficient reconstitution of freeze dried plasma

• Overcomes the logistical and operational limits of traditional plasma products - freezers, thawing equipment, long thaw times, and post-thaw refrigeration1,2

1. Pusateri AE, Given MB, Schreiber MA, et al. Dried plasma: state of the science and recent developments. Transfusion. 2016;56 Suppl 2:S128-S139. doi:10.1111/ trf.13580

2. Hervig T, Doughty H, Ness P, et al. Prehospital use of plasma: the blood bankers' perspective. Shock. 2014;41 Suppl 1:39-43. doi:10.1097/SHK.0000000000000144

Rx Only

See appendices to this presentation for EZPLAZ™ Freeze Dried Plasma Indications and Important Safety Information.

7 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Innovation Updates

• Announced four-year follow-up data from the single-arm BIOMAG-I study, confirming the long-term, sustained performance of FreesolveTM RMS 1

• Favorable long-term safety profile, with no new cardiac-related events observed between the two and four-year follow-up1

  Advancing the Clinical Program: BIOMAG-II and BIOMAG-III

• BIOMAG-II: initial European & Asia Pacific randomized controlled trial

  • Completed patient enrollment ahead of schedule

  • One-year follow-up data vs. XIENCETM Drug-Eluting Stent (DES) expected in late 2027

• BIOMAG-III: U.S. pivotal trial

  • Study will enroll 1,859 patients at up to 120 sites worldwide, comparing FreesolveTM RMS to the XIENCETM Drug-Eluting Stent (DES) on 12-month target lesion failure rate*

  • First patient procedure completed in June at MedStar Health

*Target Lesion Failure is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave Myocardial Infarction, or clinically driven Target Lesion Revascularization (TLR).

1.Torzewski, J. Lessons from the long-term DES data: how they can inform today's practice - BIOMAG-I: 4-Year Clinical Outcomes of the Resorbable Magnesium Scaffold-DREAMS 3G. pcronline.com Published May 20, 2026. Accessed June 3, 2026. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2026/ EuroPCR/Lessons-from-the-long-term-DES-data-how-they-can-inform-today-s-practice?auth=true. Research sponsored by Teleflex.

CAUTION-Investigational device. Limited by the United States law to investigational use.

FreesolveTM RMS is not for sale in the United States and is commercially available in CE-mark accepting countries only. Indications for Use may vary by geographic location.

8 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Q2'26 Global Product Commentary of Continuing Operations

Sales ($M) Commentary

$246.3

Reported rev. growth: 9.0% Pro forma adj. const. curr. rev. growth: 8.0%

• In Q2'26 growth was primarily driven by growth in hemostatic products and the central access portfolio

  Interventional

$211.9

Reported rev. growth: 86.1% Pro forma adj. const. curr. rev. growth: (1.0)%

$112.1

Reported rev. growth: 9.1% Pro forma adj. const. curr. rev. growth: 9.2%

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. Pro forma adjusted constant currency revenue growth is as compared to the prior year period.

9 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Q2'26 Global Product Category Revenue Review

Three Months Ended June 30, 2026

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

1. Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments

2. Adjustments are inclusive of discontinued product adjustments

10 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Financial Overview

Q2'26 Financial Review of Continuing Operations

Adjusted GAAP

2025

2026

(280)

bps

• The year-over-year adjusted gross margin decline was primarily driven by the following:

  2025 60.1%

  2026 58.2%

  2025 31.1%

  2026 37.4%

  2025 6.0%

  2026 7.9%

  • the adverse impact of tariffs

  • the addition of the Vascular Intervention business, which has a slightly lower gross margin than the corporate average

• The year-over-year adjusted SG&A expense % of sales increase was driven by the following:

  • operating expenses associated with the acquired Vascular Intervention business

    2025 33.9%

    2026 34.2%

    2025 5.8%

    2026 7.8%

    R&D Expense

    (% of Sales)

2025

2026

2025

2026

(520)

bps

2025

2026

• The year-over-year adjusted operating margin decline was driven by the following:

  2025 20.6%

  2026 12.8%

  • year-over-year gross margin pressure

  • higher operating expenses associated with the acquired Vascular Intervention business as well as increased R&D investment

    $1.54

    $0.96

• The year-over-year adjusted earnings per share increase was driven by the following:

  • a lower share count and tax rate and, to a lesser extent, higher adjusted operating income

  • partially offset by tariffs and higher interest expense

Note: See appendices for reconciliations of non-GAAP financial information.

12 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Capital Allocation Strategy Update

Capital return commitment

• $1 billion share repurchase authorization and $800 million reduction in debt

• Near-term capital return to shareholders to be primarily funded by after-tax proceeds from the Strategic Divestitures

  Q2 share repurchases

• Repurchased approximately 1.9 million shares for $250 million through open market transactions

• Average price of $130.85 per share, under the previously announced $1 billion repurchase authorization

  OEM divestiture proceeds deployment

• With the close of the OEM divestiture, which resulted in proceeds of approximately $1.5 billion and estimated after-tax proceeds of $1.25 billion, intend to commence a $250 million accelerated share repurchase (ASR) on August 7

• Remaining net proceeds from OEM divestiture to be used primarily to:

  • Pay down the $700 million Term Loan A-2 associated with the Vascular Intervention acquisition

  • Replenish funds deployed for the $250 million share repurchase completed during the second quarter

13

2026 Financial Guidance

Revenue

• Reducing 2026 pro forma adjusted constant currency revenue growth range to 3.50% to 4.5% year-over-year

• Reducing 2026 GAAP revenue from continuing operations growth range to 13.40% to 14.4% year-over-year

Earnings Per Share

• Increasing 2026 Adjusted diluted EPS from continuing operations range to $6.90 to $7.20

• Reducing 2026 GAAP EPS from continuing operations range to $2.54 to $2.84

14

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

2026 Guidance Considerations

Adjusted Earnings Per Share

• 2026 adjusted EPS from continuing operations in the range of $6.90 to $7.20

  
  
  

• Assumes:

  • ~19.0% adjusted operating margin inclusive of transition services ("TS") associated with the close of the OEM Strategic Divestiture

  • ~12.25% tax rate

  • $85M of interest expense

  • Reflects capital allocation execution: $250M share repurchases in Q2 2026 and payoff of ~$700M Term Loan A-2

  • Excludes TS and manufacturing services ("MS") benefits from the Acute Care & Interventional Urology Divestiture

  • Excludes the $250M ASR and future repurchases under the $1B buyback program funded by Strategic Divestitures proceeds

  • Excludes potential IEEPA tariff refund impact

  • Excludes incremental debt paydown with net proceeds from the Strategic Divestitures

    Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

    15

    2026 Financial Guidance - Future Opportunities

    Adjusted Operating Margin

  • TS/MS agreements expected to offset stranded costs on an annualized basis

  • Previously announced restructuring programs to result in ~$50 million of pre-tax savings on an annualized basis upon completion in mid-2028, which will contribute to mitigating stranded costs

Debt Paydown

• Intend to pay down ~$800 million in debt, including debt associated with the Vascular Intervention acquisition, with net proceeds from the Strategic Divestitures

Share Repurchase

• Remaining $750 million authorization under previously announced share repurchase program to be funded with net proceeds from the Strategic Divestitures

16

2026 Financial Guidance of Continuing Operations Summary

Note: See appendices for reconciliations of non-GAAP financial information.

17 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation

Note: See appendices for reconciliations of non-GAAP financial information.

18 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Key Takeaways

• Vascular & Surgical delivered excellent H1 results

• Interventional integration slower than planned; mitigations underway

• Reduced adjusted revenue guidance to reflect dynamics

• Executing to total of $1B share repurchase & $800M debt reduction

• Accelerated capital reallocation in H1 driving increase in adjusted EPS guidance

• Completed OEM divestiture will fuel additional repurchases & debt reduction

• Successfully executing towards more streamlined portfolio

• Meaningfully stronger financial profile starting in 2027

• Positive innovation milestones highlight increased focus on future growth opportunities

19 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Thank You!

20 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026